Antipsychotic prescriptions among adults with major depressive disorder in office-based outpatient settings: National trends from 2006 to 2015

Journal of Clinical Psychiatry

Volumn 79, Issue 2, 2018, Pages

  Rhee, Taeho Greg ^a,b   Mohamed, Somaia ^a,c,d   Rosenheck, Robert A ^a,c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c Education and Clinical Centers (MIRECC)   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; LOXAPINE; LURASIDONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE; ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BLACK PERSON; CANNABIS ADDICTION; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISPANIC; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICARE; MENTAL HEALTH; OUTPATIENT CARE; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; CLASSIFICATION; CLINICAL PRACTICE; EPIDEMIOLOGY; ETHNOLOGY; INTERNATIONAL CLASSIFICATION OF DISEASES; MIDDLE AGED; OUTPATIENT; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; TREATMENT RESISTANT DEPRESSION; UNITED STATES;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICARE; MIDDLE AGED; OUTPATIENTS; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 85046900726     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.17m11970     Document Type: Article

References (26)

1. Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health. HHS Publication No. SMA 16-4984, NSDUH Series H-51. SAMHSA website. https://www. samhsa.gov/data/sites/default/files/NSDUHFFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.htm#mhi. 2016.
2. Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015;23(1):1-21. PubMed CrossRef
3. World Health Organization. Depression: fact sheet. WHO website. http://www.who.int/mediacentre/factsheets/fs369/en/. 2017.
4. Rhee TG, Schommer JC, Capistrant BD, et al. Potentially inappropriate antidepressant prescriptions among older adults in officebased outpatient settings: national trends from 2002 to 2012 [published online ahead of print July 20, 2017]. Adm Policy Ment Health. PubMed CrossRef
5. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179-200. PubMed CrossRef
6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry. 2006;163(11):1905-1917. PubMed CrossRef
7. Fava M. Diagnosis and definition of treatmentresistant depression. Biol Psychiatry. 2003;53(8):649-659. PubMed CrossRef
8. Department of Veterans Affairs and Department of Defense. VA/DoD clinical practice guideline for the management of major depressive disorder. 2016. VA.gov website. https://www.healthquality.va.gov/guidelines/MH/mdd/MDDFullFinal5192016. pdf.
9. Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(suppl 1):S29-S37. PubMed CrossRef
10. Mohamed S, Johnson GR, Chen P, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA. 2017;318(2):132-145. PubMed CrossRef
11. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991. PubMed CrossRef
12. Philip NS, Carpenter LL, Tyrka AR, et al. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother. 2010;11(5):709-722. PubMed CrossRef
13. Han C, Wang SM, Kato M, et al. Secondgeneration antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013;13(7):851-870. PubMed CrossRef
14. Gerhard T, Stroup TS, Correll CU, et al. Antipsychotic medication treatment patterns in adult depression [published online ahead of print July 5, 2017]. J Clin Psychiatry. PubMed CrossRef
15. Mohamed S, Johnson GR, Vertrees JE, et al. The VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) study: rationale and design considerations. Psychiatry Res. 2015;229(3):760-770. PubMed CrossRef
16. Spina E, Trifirò G. Pharmacovigilance in Psychiatry. New York, NY: Springer Berlin Heidelberg; 2015.
17. Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the US Department of Veterans Affairs. J Clin Psychiatry. 2009;70(6):906-912. PubMed CrossRef
18. National Center for Health Statistics. Ambulatory health care data. CDC website. https://www.cdc.gov/nchs/ahcd/index.htm. 2017.
19. National Center for Health Statistics. Ambulatory health care data: questionnaires, datasets, and related documentation. CDC website. https://www.cdc.gov/nchs/ahcd/ahcd- questionnaires.htm. 2017.
20. American Society of Health-System Pharmacists. American Hospital Formulary Service (AHFS) Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2017.
21. Bhalla IP, Stefanovics EA, Rosenheck RA. Clinical epidemiology of single versus multiple substance use disorders: polysubstance use disorder. Med Care. 2017;55(suppl 9 suppl 2):S24-S32. PubMed CrossRef
22. Rhee TG, Capistrant BD, Schommer JC, et al. Effects of depression screening on diagnosing and treating mood disorders among older adults in office-based primary care outpatient settings: an instrumental variable analysis. Prev Med. 2017;100:101-111. PubMed CrossRef
23. Stata Statistical Software: Release 13 [computer program]. College Station, TX: StataCorp LP. 2013.
24. US Food and Drug Administration. Information on conventional antipsychotics. FDA website. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ucm107211.htm. 2008. Accessed October 1, 2017.
25. US Food and Drug Administration. Information for Healthcare Professionals: Conventional Antipsychotics. FDA website. https://www.fda. gov/Drugs/DrugSafety/ucm124830.htm. 2008. Accessed October 9, 2017.
26. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227-2246. PubMed CrossRef